International pharma Boehringer Ingelheim and prescription digital therapeutics company Click Therapeutics have inked a $500 million-plus deal to jointly develop and commercialize a digital treatment for patients with schizophrenia. [Read more…] about Click Therapeutics and Boehringer Ingelheim partner to develop and market a digital therapeutic to treat schizophrenia
These 10 European tech startups want to help you improve your mental fitness (Silicon Canals):
“According to a report by WHO Euro (World Health Organisation Europe), in many western countries, mental health disorders are the major cause of disability, accounting for 30% to 40% of chronic sick leaves, and costing nearly 3% of GDP. In addition to this, [Read more…] about Digital mental health taking off in Europe
Psychiatric diagnosis ‘scientifically meaningless’ (Science Daily):
“A new study, published in Psychiatry Research, has concluded that psychiatric diagnoses are scientifically worthless as tools to identify discrete mental health disorders.
The study, led by researchers from the University of Liverpool, involved a detailed analysis of five key chapters of the latest edition of the widely used Diagnostic and Statistical Manual (DSM), on ‘schizophrenia’, ‘bipolar disorder’, ‘depressive disorders’, ‘anxiety disorders’ and ‘trauma-related disorders’ [Read more…] about Study finds psychiatric diagnoses to be ‘scientifically meaningless’
Epigenetic Changes Guide Development of Different Brain Regions (Dana Foundation):
“It’s one of the greatest standing mysteries in neuroscience: Given that each cell in the human body contains the same DNA, how, exactly, does the brain develop into distinct functional regions, supported by different cell types? And how might that developmental program go awry, resulting in neurodevelopmental disorders like schizophrenia or autism? The answers may be the epigenome [Read more…] about Epigenetics research opens potential door to prevent neurodevelopmental disorders
Psychedelics in Neurology: Potential for Improving Neuroplasticity (NeurologyTimes):
“Back in the 1950s, research was proving that psychedelic agents could be effective in the treatment of various neuropsychiatric disorders. Unfortunately, just as science was exploring their beneficial effects, the counterculture was exploring and embracing their effects. Slowly but surely, psychedelics were associated with rebellious youth and the tumultuous anti-war movement. As a result, the government shut down most of the research.
The 1990s saw renewed interest in psychedelic compounds as a means to address neuropsychiatric disorders. Research explored the benefits of MDMA and ketamine to treat mood disorders and posttraumatic stress disorder. Now, a new study sheds even more light on the promise these agents might provide. [Read more…] about Study: Psychedelics can promote neural plasticity in the prefrontal cortex and expand pathways for mental health
Happy to share that the Luria Neuroscience Institute, an esteemed Partner of the 2017 SharpBrains Virtual Summit, is hosting a new webinar series aimed at better equipping professionals helping those with mental health and with brain and brain disorders.